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Decision modelling of non-pharmacological
interventions for individuals with dementia:
a systematic review of methodologies
Elizaveta Sopina1* and Jan Sørensen1,2
Abstract
Objectives: The main objective of this study is to conduct a systematic review to identify and discuss
methodological issues surrounding decision modelling for economic evaluation of non-pharmacological
interventions (NPIs) in dementia.
Methods: A systematic search was conducted for publications using decision modelling to investigate the cost-
effectiveness of NPIs for individuals with dementia. Search was limited to studies in English. Studies were excluded
if they evaluated interventions aimed only at caregivers of patients with dementia, or if they only included
economic evaluation alongside an RCT without additional modelling.
Results: Two primary, five secondary and three tertiary prevention intervention studies were identified and
reviewed. Five studies utilised Markov models, with others using discrete event, regression-based simulation, and
decision tree approaches. A number of challenging methodological issues were identified, including the use of
MMSE-score as the main outcome measure, limited number of strategies compared, restricted time horizons, and
limited or dated data on dementia onset, progression and mortality. Only one of the three tertiary prevention
studies explicitly considered the effectiveness of pharmacological therapies alongside their intervention.
Conclusions: Economic evaluations of NPIs in dementia should utilise purposefully-developed decision models,
and avoid models for evaluation of pharmaceuticals. Broader outcome measures could be a way to capture the
wide impact of NPIs for dementia in future decision models. It is also important to account for the effects of
pharmacological therapies alongside the NPIs in economic evaluations. Access to more localised and up-to-date
data on dementia onset, progression and mortality is a priority for accurate prediction.
Keywords: Dementia, Economic evaluation, Decision modelling, Non-pharmacological interventions
Background
Dementia is a common syndrome, mostly affecting the
elderly and is characterised by progressive loss of mem-
ory and cognitive function [1]. Estimates suggest that
the prevalence of dementia is between 5.9 and 9.4%
amongst people aged 65 and over [2, 3]. Both the num-
ber of people with dementia and costs of treatment have
been rising rapidly in the past two and a half decades
[4]. Given the impending ageing population and limited
health care resources, reliable and valid cost-
effectiveness analyses of interventions targeted at people
with dementia is an important task for both researchers
and policy makers [5].
Most of interventions available for people with dementia
are of pharmacological nature, aiming to either relieve
symptomatic aspects of the condition, or delay the process
of cognitive deterioration [6]. Although these have had a
positive impact, the scope and effectiveness of these drugs
have been questioned [4, 7]. In particular, available phar-
maceuticals appear to have little or no effect on behav-
ioural and functional outcomes [8]. The high cost and
limited success in developing new pharmaceuticals has led
to suggestions that a different, broader approach to deal-
ing with dementia is required [7].
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Such an approach can include delaying onset by controlling
modifiable lifestyle factors, such as smoking, obesity and exer-
cise (primary prevention), timely identification of the disease
(secondary prevention) and post-diagnostic interventions
aimed at improving quality of life and delaying progression of
dementia (tertiary prevention) [4, 9, 10]. A broader approach
to dealing with dementia is given increasing importance and
a growing number of studies investigating novel, non-
pharmacological approaches to treating, managing and sup-
porting people with dementia and their carers have been
emerging [11]. In fact, the number of studies investigating the
effectiveness of non-pharmacological interventions (NPIs)
has been growing fast in the last 15 years [10]. These inter-
ventions target a wide spectrum of dementia symptoms:
not only cognitive decline, as most pharmaceuticals, but
also psychological, behavioural aspects, as well as func-
tional abilities/activities of daily living, among others [10,
12–15].
While some evidence for cost-effectiveness of NPIs ex-
ists [16], the majority of economic evaluations of demen-
tia interventions focus on pharmacological therapies.
Contrasted with the number of NPIs available, a wide
gap in economic evaluation of such interventions is evi-
dent: in their review of decision analytic models for Alz-
heimer’s disease (AD; the most prevalent type of
dementia), Cohen and Neumann [17] found that many
of the existing models for economic evaluation of
pharmacological AD interventions are not suited for as-
sessment of NPIs. In fact, all economic models aimed at
evaluating interventions for dementia identified in a sys-
tematic review by Green, Shearer, Ritchie and Zajicek et
al. [18] were created for the purpose of evaluating cost-
effectiveness of a pharmaceutical.
Further, application of pharmacological models to
NPIs is problematic, given the differences in aims, scope
and assumptions behind the two types of interventions.
While the main concern of pharmacological interven-
tions is slowing the progression of dementia, NPIs often
have a much broader scope, thus requiring an outcome
measure with a broader scope than just cognition. NPIs
also consider the interaction between the patient, their
caregiver and their environment, including the medical
and support systems in place – something that is often
disregarded in pharmacological evaluations [10, 13, 15].
The time horizon of NPIs, and, in particular, those with
a preventative or screening focus, is also likely to be dif-
ferent to pharmacological therapies. It is therefore rea-
sonable to expect that methodologies for evaluation of
NPIs should be different from those used for evaluating
pharmacological interventions.
A recent review has demonstrated that pharmaco-
logical treatments are significantly costlier than NPIs,
thus posing a significantly higher economic burden on
healthcare budgets [4]. However, the authors did not go
as far as to compare cost-effectiveness of pharmaco-
logical interventions with NPIs, partially due to the
short-term nature of trials available, as well as small
numbers of people participating in those. A potential so-
lution to this is extrapolation of data and characterising
uncertainty through decision modelling.
Given the growing impact of dementia on health out-
comes and services, and the continuing development of
new NPIs, it is important to foster a strong understanding
of methodologies available for economic decision model-
ling in dementia. A number of existing reviews have inves-
tigated decision modelling in dementia [17–19], but none,
to the best of our knowledge, have focussed solely on
NPIs.
This paper is aimed at researchers and policy makers
working on economic evaluation of NPIs for dementia.
In this paper we set out to provide a detailed overview
of current methods available for decision modelling of
NPIs for people with dementia, identify and discuss
methodological issues surrounding decision modelling
for economic evaluation of non-pharmacological inter-
ventions (NPIs) in dementia, in particular with respect
to model structure, outcome measures and data inputs.
Methods
The systematic review followed the methodology pro-
posed by the Cochrane Handbook for Systematic Re-
views of Interventions and was reported in accordance
with Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) [20, 21].
Search sources and strategy
A literature search was conducted on the 7th July 2017 on
PubMed, Scopus, Science Direct, Cochrane, NHS EED,
Embase, EconLit and Psychinfo databases. Detailed search
strategy for each database is presented in Additional file 1.
The search was limited to studies published in English.
The search did not include studies published prior to
2000, for a number of reasons: there were few NPIs for
dementia developed before the year 2000 [10], studies be-
fore 2000 were covered by broader reviews and do not re-
veal many decision models on NPIs [17–19], and
modelling techniques used prior to 2000 are likely to have
been significantly improved and perfected [22].
Study eligibility was established on initial screening of
title and abstract. Studies passing initial screening were
subject to full text review against inclusion and exclusion
criteria, outlined in Table 1. Studies were included if they
modelled the onset and/or progression of dementia, and
evaluated the cost-effectiveness of a NPI aimed at people
at risk of or with dementia. All study designs were consid-
ered for review. Studies were excluded if they evaluated
interventions aimed only at caregivers of patients with
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dementia, or if they only included economic evaluation
alongside an RCT without additional modelling.
Review process
The nature of the intervention should, at least in
part, dictate the structure of the model, and, therefore
the necessary inputs such as transition probabilities,
utilities, costs etc. [22]. Therefore, the analysis of
studies selected for this review is focused on three
categories of NPIs: primary, secondary and tertiary
prevention, as defined previously. Primary prevention
includes interventions aiming to preventative or delay
onset of dementia, secondary prevention interventions
include screening and early identification initiatives,
whilst interventions in the tertiary prevention cat-
egory focus on aiding the symptoms and/or slowing
the progression of the disease after a diagnosis has
been made. Key features of the included studies were
summarised, with specific focus on model structure,
outcome measures and characterisation of disease on-
set and progression. These were selected to reflect
the most significant aspects of modelling dementia-
related interventions [18, 23], with particular rele-
vance to evaluation of NPIs.
Methodological approaches were described with a view
to identify common challenges and possible improve-
ments for future model-based economic evaluations of
NPIs for dementia. This was done by examining the
studies against two widely-used best-practice guidelines
for decision modelling in economic evaluation [24, 25].
Data used in reviewed models were assessed for the rele-
vance in terms of date, setting, sample size and method
of collection. In cases where studies utilised secondary/
published data, we reviewed the data at the cited source.
Results
After duplicates were removed, 1024 studies were identi-
fied, of which 998 were excluded after the initial screening
(Fig. 1). The main reasons for exclusion were: pharmaco-
logical nature of the intervention; models not simulating
Table 1 Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
- Original decision model
- Study models onset and/or
progression of dementia
- Published in or after 2000
- Assesses health-economic
impact of intervention
through cost-effectiveness,
-benefit, -utility or
-minimisation analysis
- Assesses a non-pharmacological
intervention targeting dementia
- Pharmacological intervention
only
- Intervention targeting solely
caregivers of patients with
dementia
Fig. 1 Flow chart for selection of studies included in the systematic review
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dementia onset or progression, or interventions that solely
targeted caregivers of AD or dementia patients. We also
excluded systematic reviews and editorials, as well as stud-
ies not written in English, and those that were not AD- or
dementia-specific in their focus. Studies utilising the same
model as an already included study were also excluded
from this review.
A total of ten studies were included in the review. An
overview of the selected studies is presented in Table 2
and each study is briefly summarised in Additional file 2.
Approach to modelling and model structure
Structure of the model should be transparent and justified
given the aim, scope and perspective of the model [25]. It
should also be possible to reproduce the model from the
technical information provided to the reader [24].
Of the ten reviewed studies, five [26–29] used Markov
modelling techniques to simulate dementia or AD pro-
gression. The others included a Monte-Carlo model
[30], three decision trees [27, 31, 32] and a regression-
based simulation model [33]. There was no evident pat-
tern of model preference in primary, secondary or ter-
tiary prevention studies. In all reviewed studies, little or
no rationale was given for the choice of model, and,
while model choices did appear appropriate for purpose,
it is advisable to include a justification or rationale for
the choice of methods [24, 25].
The state-transition Markov models utilised in the five
studies were reasonably simple in structure, consisting
either of three to four health states (‘non-demented/
non-AD’, ‘Mild cognitive impairment’, ‘demented/AD’ and
‘dead’) or five to six states, where ‘demented/AD’ was
further broken down into various degrees of severity.
While maintaining a simple approach to modelling does
require fewer data inputs and, therefore, also exposes
the findings to fewer biases, it may also limit the accur-
acy of the model predictions. It is possible that the
choice of health states included is most likely influenced
by data availability. Four interventions utilised 12-
month cycles [26, 27, 29, 34]; McMahon and colleagues
modelled disease progression in 6-week cycles [28].
Cycle length has an impact on model predictions:
shorter cycles may improve accuracy, in particular, with
regards to survival time, but do require more detailed
data.
Two decision tree-based models evaluated screening
methods for dementia [31, 35] and one evaluated a pre-
ventative treatment [36]. The model by Silverman and
colleagues [31] is not transparent, as only a schematic
flow of decisions during a screening process is pre-
sented, not the actual model structure. Similarly, Dixon
et al. only provide a textual description of the model
[35]. It is questionable whether the two models could be
reconstructed on the basis of the information provided.
Tsiachristas and Smith [32] present a stochastic decision
model for evaluating the cost-effectiveness of preventa-
tive treatment with B-vitamin. The model is not de-
scribed in great detail, nor represented schematically,
although parameters used provide some guidance as to
how the model is structured [37].
A parametric Monte Carlo model was built to evaluate
the cost-effectiveness of early diagnosis and intervention
in AD [30]. The model is described in some detail, and
with the aid of specified parameters, it is feasible to pre-
sume the model to be reproducible.
McDonnell et al. [33] assessed the cost-effectiveness of
a potential treatment compared to standard care by
simulating two cohorts of patients with AD using two
regression-based simulation models. The models simu-
lated the changes in cognitive decline as measured by
Mini-Mental State Examination (MMSE), care setting
and mortality of people with AD and compared the costs
and effects of the strategies. The models were based on
primary data from an epidemiological trial [38] and re-
producing the model predictions without access to this
data may prove difficult.
Comparators used and number of treatments compared
Best practice modelling guidelines recommend that all
feasible and practical strategies are considered in deci-
sion models [24]. Of the ten studies reviewed, only two
assessed more than two comparators. The Monte Carlo
model by Weimer and Sager compared two identifica-
tion strategies (early and delayed), but then applied four
hypothetical treatments after diagnosis (pharmacological,
nonpharmacological and mix of the two types) [30]. The
Markov model constructed by McMahon et al. also
compared four screening strategies in base-case, as well
as four additional strategies in sensitivity analysis; these
included standard screening, a range of different inten-
sities of screening methods, as well as a no-screening
option [28].
The remaining four of the five Markov models com-
pared two alternatives – usual care/treatment and new
intervention [26, 29, 34]. All three decision tree models
compared only two alternatives – no/current interven-
tion with the new intervention [31, 32, 35]. McDonnell
and colleagues also compared the impact of two inter-
ventions: a hypothetical treatment and standard care
[33]. No or little justification for omission of other com-
parators has been provided by the authors in these
studies.
Of three tertiary prevention studies, only one [29]
stated explicitly that standard pharmacological inter-
vention was assumed to have been provided alongside
the new treatment, in order to compare the new
treatment with ‘standard care’ alone. The other two
post-diagnostic studies did not explicitly state that
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they included standard pharmaceutical care alongside
their new treatment [33, 34].
Time horizon
Decision modelling guidelines recommend that the time
horizon of a study should be sufficiently long to capture
all the differences of the strategies being assessed; this
may require a lifetime horizon [24, 25]. Dementia is a
chronic condition for which there is no cure; it also
negatively affects survival times [39], suggesting that au-
thors conducting economic evaluations of dementia in-
terventions should pay special attention to ensure all
intervention effects are captured.
Only three studies utilised a lifetime time horizon in
their model [30, 32, 35] which is the most appropriate
approach, in particular for risk-prevention or screening
interventions, where health impacts and associated costs
may not manifest for a long time after intervention.
However, given the late average age of onset for demen-
tia and the age at which patients are exposed to inter-
vention, a 10 or 20 year time horizon may be
appropriate; such time horizons were observed in three
other included studies [26, 27, 33]. Of the three tertiary
prevention interventions reviewed, time horizons were
either 10 or 5 years. The latter was utilised by
Mirsaeedi-Farahani et al. [34] and Martikainen et al.
[29], who adapted a model initially designed for evalu-
ation of pharmaceuticals. However, given that the psy-
chosocial nature of the intervention, the five-year time
horizon may not capture all the costs and effects related
to the intervention.
Choice of outcome measure
Quality adjusted life years
When using preference-based measures for health out-
comes, such as health utilities, to calculate Quality-
Adjusted Life Years (QALYs), decision modelling guide-
lines recommend that the utility weights are incorporated
into the model appropriately, and the methods for deriv-
ation of utility weights are justified [25].
Four studies employed QALYs as their key outcome
measures [26, 28, 32, 34]. McMahon and colleagues [28]
classified quality of life measures by disease severity (mild,
moderate and severe) as well as residential status (com-
munity or nursing home), resulting in six different util-
ities. The utility weights were obtained from a US study,
which used Health Utility Index Mark 2 to gather proxy-
rated utilities of 528 caregivers of people with AD [40].
Mirsaeedi-Farahani et al. [34] provided utilities for
three levels of AD severity (mild, moderate and severe).
These were obtained from eight published studies; no
further detail was provided as to how these utility
weights were selected or calculated.
Another study calculated QALYs by multiplying years
of expected life by utility weights for people with and
without dementia, without further breakdown into se-
verity of disease [32]. The utility weights were based on
self-completed EQ-5D Visual Analogue Scale (VAS)
scores of the general population from the Health Survey
for England [32]; it is unclear how these were related to
dementia.
Zhang and colleagues [26] also did not distinguish be-
tween different stages of disease; QALYs were calculated
for people with and without dementia. Utility weights
were obtained from a Swedish population study, where
general population utilities were gathered using the EQ-
5D instrument [41]. It is unclear how the health-related
quality of life (HRQoL) of the general population was
applied to dementia.
Other outcome measures
Three of the ten reviewed studies [27, 30, 33]. included
changes in MMSE score [42] as their primary outcome.
One study utilised scores collected as part of the study
[27] Weimer and Sager [30] used MMSE scores to clas-
sify the severity of AD and ascribed varying health care
costs to each level of disease severity. MMSE decline
with and without treatment was obtained from a range
of published literature. McDonnell et al. [33] used
MMSE scores to model disease decline; MMSE scores
were based on a trial that the study followed [38].
The remaining studies measured outcomes using the
number of accurate/additional diagnoses [31, 35] and
time to nursing home admission [29].
Characterisation of disease progression
As both costs and health outcomes are dependent on
disease onset and severity, characterisation of disease
progression is, arguably, the most critical model input
for producing accurate estimates. In many types of deci-
sion models, disease progression is directed by progres-
sion probabilities, i.e. the probability of shifting from
one health state to another. It is advised that transition
probabilities should be derived from “the most represen-
tative data sources for the decision problem” [24].
Four studies based their disease onset and progression
parameters on a single study. McDonnell and colleagues
[33] used primary data from a large epidemiological trial
conducted in the 1990’s to inform disease onset and pro-
gression parameters [38]. These were reported by age,
gender, residential status and MMSE score. Tsiachristas
and Smith [32] based their disease onset and progression
parameters on a national report on AD [43]. Zhang et al.
[26] synthesised progression probabilities from a single
source [44], although it is not transparent how progres-
sion probabilities were arrived at. The model by Weimer
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et al. [30] used disease progression data from a single
study of 134 patients on cholinesterase inhibitors [45].
Five studies synthesised this information from two or
more studies. McMahon et al. [28] and Martikainen et
al. [29] utilised data from US-based studies [40, 46].
Martikainen and colleagues combined data from both
papers, but do not provide more detail on how this was
done. Another study [34] also utilised data from Neu-
mann et al. [46] and another US-based study [47]. Simi-
larly, Saito et al. also used data on progression of AD
from Neumann et al. [46], combining it with another
study, reporting on onset of mild cognitive impairment
from pre-dementia [48]. Silverman et al. [31] also syn-
thesised onset probabilities from two studies and pro-
vided little detail on how this was done.
Finally, Dixon et al. did not specify how disease onset
and progression was characterised in their model [35].
Survival
Survival, or mortality, from dementia was integrated into
the reviewed papers in a range of ways. McMahon and
colleagues [28] calculated the probability of death from
each stage of AD from a Neumann et al. [40], and the
probability of death for the non-AD group from US life
tables; these were not stratified by age. Weimer and
Sager [30] applied a hazard ratio (2.1) to a non-AD
population mortality rate to simulate higher rates of
mortality. The ratio was obtained from a cardiovascular
health study of the US population. Zhang and colleagues
[26] populated the model with age-specific mortality for
both AD and non-AD groups, obtaining the data from
Statistics Sweden; the study assumed the same mortality
rate for both groups.
Three papers used the same data sources for mortal-
ity/survival as for other disease progression probabilities.
Saito et al. obtained mortality data from the same source
as the other transition probabilities, by combining two
previously published studies [46, 48]. Insufficient details
were provided on how these probabilities were com-
bined. Another model [29] also used the same sources
for probabilities of death as for other transition probabil-
ities [40, 46]. These were stratified by severity of AD
(mild, moderate and severe), but not by age and gender.
Mirsaeedi-Farahani et al. [34] also used the same two
studies for mortality as for other disease progression
probabilities [46, 47]; these were stratified by severity,
but not age or gender.
One study [32] used life expectancy data to estimate
mortality in their model; UK life tables were used to cal-
culate life expectancy of non-AD group, and AD mortal-
ity was based on life expectancy obtained from another
UK study [49]. McDonnell et al. calculated probabilities
of death based on the results of a study reported in the
paper. The probability of death is reported by age, gen-
der, residential status and MMSE score [33].
Finally, two studies did not account for mortality in
their models. The study by Silverman et al. [31] did not
appear to extend far enough to calculate the impact of
screening on mortality, while the other [35] did not in-
clude mortality in their parameters, stating that it was
‘beyond the scope of the model’, although a lifetime time
horizon was utilised.
Costs
Decision modelling guidelines recommend that costs in-
cluded in the model should be consistent with the selected
perspective, reflective of all outcomes included in the
model and should also be incorporated from data sources
in a consistent manner [24, 25]. Overall, costs were con-
sistent with the studies’ perspectives. In terms of
consistency of data use, two studies estimated costs from
primary data, such as administrative registries and data-
bases [29, 33], three utilised secondary costs [27, 32, 34],
and a further four studies used a combination of second-
ary and primary data for costs, mostly complementing any
data missing from primary sources with published infor-
mation [26, 28, 30, 35]. Silverman and colleagues utilised
Medicaid reimbursement rates to estimate their costs [31].
Studies utilising secondary sources included generalised
average per patient costs for dementia, of which two used
average total annual costs [32, 34] and one included costs
per stage of dementia [27]. Studies utilising any primary
cost data used unit costs for individual aspects of diagno-
sis and treatment.
Discussion
This paper reviews a range of modelling approaches to
economic evaluation of NPIs. Although the studies
assessed in this paper provide a valuable overview of
methodologies available, each comes with limitations.
Previous reviews, focusing mainly on pharmacological
models, have discussed the limitations in terms of model
structure and characterising disease progression [18, 19].
This paper extends this body of knowledge by reviewing
decision modelling studies with a special focus on NPIs
for dementia.
The majority of tertiary prevention interventions are
not designed to replace pharmacological therapy, but ra-
ther to complement it. It is reasonable to assume that a
NPI, such as cognitive or behavioural interventions,
would be used in conjunction with standard pharmaco-
logical treatment. However, only one of the three studies
modelling tertiary prevention interventions considered
the effect of pharmaceuticals. Given that pharmaceuti-
cals do have an effect on cognition [8], omission of this
effect poses significant questions over the conclusions of
the reviewed studies. Furthermore, only two of the ten
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reviewed studies examined more than two comparators.
A larger number of alternatives courses of action would
prove more informative for decision makers.
Disease progression and outcome measures
Dementia manifests itself in a wide range of ways, in-
cluding cognitive decline, behavioural and psychological
symptoms, as well as deterioration in ability to perform
everyday tasks. NPIs for dementia have broad effects,
which include improving behavioural and cognitive
facets of dementia, as well as improving the overall well-
being of a patient (and, potentially, their caregiver).
However, this breadth of both impacts of dementia, and
interventions to address the disease, was not reflected in
the characterisation of disease progression or the breadth
of main outcome measures used to measure intervention
effectiveness in the reviewed studies. The majority of the
interventions utilised measures of cognition, such as
MMSE, to model progression of dementia. The use of
such measures to model disease progression in NPIs may
be problematic, as such interventions often not only focus
on slowing progression of the disease, but also on inde-
pendence of patients and quality of life (both patients’ and
caregivers’) such as those assessed in Martikainen [29].
Single-faceted measures of dementia, such as cognition,
are also unlikely to fully capture the breadth of the burden
imposed by dementia, nor the equally broad impacts of
NPIs. This is likely to affect cost and outcome estimates in
decision models. An alternative approach could be to
characterise disease progression using an alternative con-
cept, such as dependence, or a multi-domain model of
disease progression [50, 51]. Broadly, these concepts rep-
resent progression of dementia as a function of cognitive,
behavioural and activities of daily living aspects of demen-
tia. These allow to classify the burden of disease, and asso-
ciated costs and outcomes more accurately. It has also
been proposed that QALYs and costs associated with each
stage of disease can be mapped on to the measure and
used in decision modelling [50].
However, the application of these concepts would re-
quire additional work and further development of instru-
ments, as neither of the concepts are yet fully developed
and ready for application [50–52]. The.
MMSE is a commonly used measure for cognitive abil-
ity, it is easy and relatively cheap to administer and can
be categorised to define stages of cognitive deterioration.
However, MMSE and other measures of cognitive de-
cline are surrogate end-points, and their use in cost-
effectiveness analysis has been questioned [53], as it is
difficult to establish a cost per incremental change on
such a scale. Demographic characteristics of a patient
can also be a determinant of cognitive capacity, and this
is often not accounted for. Furthermore, measures of
cognitive decline do not reflect patients’ or caregivers’
preferences.
A number of reviewed studies used QALYs as an out-
come measure. HRQoL measures may capture the effect
of an intervention on both morbidity and mortality, and
provide a common denominator for comparison of eco-
nomic evaluations across diseases; however, they also are
subject to a number of limitations. For the purposes of
brevity, this discussion will focus solely on issues relating
to the subject of dementia.
Increase in severity of dementia corresponds with de-
creased cognitive function, memory loss, and, eventually,
physical decline. These changes have a significant effect
on the quality of life of a person with the disease, and
should be accounted for in an economic evaluation.
Two of the four reviewed studies that used QALYs as an
outcome measure did not differentiate between stages or
severity of dementia, simply providing utility values for
either having or not having dementia. This is likely to
significantly impact on the accuracy of the findings.
Furthermore, some studies combined utilities from a
range of different sources, without providing a justifica-
tion for why, or an explanation of how. Another import-
ant aspect in measuring HRQoL in people with
dementia is the loss of cognitive function, which impairs
judgement and ability to complete these relatively com-
plex questionnaires. In order to avoid this, proxy-
completion by caregivers is often used. However, there is
evidence of significant discrepancy between self- and
proxy-completed HRQoL measures for people with de-
mentia [54, 55]. It is important to recognise these poten-
tial biases in outcome measures for future studies.
Original vs adapted models
Adapting a model initially designed for evaluation of a
pharmacological intervention could be the reason be-
hind the choice of an outcome measure [28, 29]. Such
models utilise clinical end-points which are used to
measure the effectiveness of a pharmaceutical, which
may not be sufficiently broad for NPIs, as previously dis-
cussed. Models developed for pharmacological interven-
tions also focus on the period during which medication
is taken, often resulting in short time horizons. When
applied to a NPI for dementia, this is likely to omit the
longer lasting effects of the intervention, and associated
costs. In this review, purposefully-designed models
tended to have longer time horizons, and also measure
outcomes with QALYs, rather than cognitive-based
measures.
Decision modelling in NPI for dementia should be
conducted using models developed for the purpose.
Purpose-developed model are likely to better reflect the
features of NPIs, such as broad impacts, more appropri-
ate time-horizons to capture all relevant costs and
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outcome, and more appropriate characterisation of dis-
ease progression.
Data
A major concern is the availability and accuracy of pa-
rameters for disease onset and progression, as well as
mortality data. The majority of data on disease onset,
progression and mortality used in the included studies
were obtained from literature, and, in many cases, from
multiple foreign (often US-based) sources.
Synthesising progression probabilities from a range of
published sources may be problematic for a number of
reasons. First, mortality varies dramatically across the
world due to a range of socioeconomic, health care, edu-
cational and other factors. Secondly, some of the data
were collected in the 1990’s, and both mortality patterns
and treatments available have changed significantly since
then. This generalisability issue may result in inaccurate
predictions of disease-related mortality. However, it is
fair to note that this arises due to the lack of appropriate
data on disease progression, rather than the quality of
research presented. Finally, the methodological differ-
ences in calculation of probabilities for disease onset,
progression and mortality, and assumptions made during
the calculations, may mean that combining data from
different studies may reduce the reliability of these
inputs.
Data generalisability issues are also highly relevant for
mortality data. There is strong evidence to indicate that
age, gender, and severity of dementia affect mortality
rates [39, 56]. Only one reviewed study parametrised
mortality by age, gender, and severity; others focused
only on severity. Two studies omitted survival altogether,
with one declaring a lifetime horizon for their study. Fu-
ture decision models of interventions in dementia could
consider including mortality and stratifying it by age,
gender and severity of dementia for more accurate
predictions.
This indicates a need for more detailed and localised
data on disease onset, progression and mortality, and
stratifying such data by demographic factors such as age
and gender. Alternative ways of characterising disease
progression, such as dependence and health state util-
ities, should also be given consideration in future re-
search. Overall, most studies would benefit from
employing a more robust approach to economic evalu-
ation in this field, by following a checklist or guidelines
for economic evaluation studies such as those outlined
by Philips et al. [25] and Caro et al. [24].
Strengths and limitations
The findings of this review may be limited by the restric-
tion of the review to English-language studies only and
only assessing the methodology, and not the findings, of
the included studies.
The studies included in this review were relatively
heterogenous, representing a range of NPIs as well as
modelling methods. However, as we are focusing on
methodology, not results, of studies, this should not be a
critical factor. We reviewed ten models on NPIs, of
which only three evaluated tertiary prevention interven-
tions. This is in stark contrast to the large number of
NPIs targeting cognitive, behavioural and functional as-
pects of dementia [13, 15]. It is difficult to isolate one
reason for this disparity; although the issues of data
availability could be contributing factors.
This study followed robust methodology outlined by
the Cochrane Handbook for Systematic Reviews of In-
terventions [20]. To the best of our knowledge, this is
the first study to review modelling in NPIs for dementia.
It is a growing field and the number of new interven-
tions requiring economic evaluation is growing rapidly.
Our study provides an insight into methods and data re-
quirements for decision modelling in this area.
Conclusions
In this paper we reviewed ten economic models that
evaluated NPIs for patients with dementia. Economic
evaluations of NPIs in dementia should utilise
purposefully-developed decision models, and avoid
models for evaluation of pharmaceuticals. A major
methodological shortcoming identified in this review is
the limitation of cognition-focused outcome measures,
as they only capture one dimension of a broader range
of outcomes NPIs offer. Application of HRQoL mea-
sures may also introduce biases and may not completely
capture the effects of NPIs. A broader outcome measure,
such as dependency, could be considered as an alterna-
tive for modelling disease progression. It is also import-
ant to account for the effects of pharmacological
therapies alongside the NPIs in economic evaluations.
We also identified a lack of data availability and accuracy
on onset, progression and mortality from dementia.
There is a considerable need for development of country
or region-specific data based on larger longitudinal
studies.
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